Barcelona biotech, a spin-off of Pompeu Fabra, developing the FiCAT gene writing platform for next-generation CAR-T therapies.
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Seed Integra Therapeutics raised €10.7 million in a pre-Series A round led by the EIC Fund and CDTI Innvierte to bring the FiCAT gene writing platform to preclinical validation. | $12.4M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.